This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ThousandOaks-based Amgen and venture firm Kleiner Perkins Caufield & Byers have put their backing behind a new, Westlake Village based drug development firm, Atara Biotherapeutics , in an unusual spinout of technology from the biotech giant. Financial details of the funding were not announced.
ThousandOaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Source of the new funding was not disclosed. The filing indicates the round came from five investors.
ThousandOaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.
ThousandOaks-based Amgen has helped to back a new, life sciences fund, managed by San Francisco-based venBio , as an anchor supporter of a new fund. venBio did not say how much Amgen committed to the fund, which is venBio's second life sciences fund. READ MORE>>.
ThousandOaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital.
ThousandOaks-based Ceres , a developer of biofuels crop technology, said Thursday that it has completed a private offering of convertible preferred stock. The funding came from Artal Luxembourg, Ambergate Trust, Gimv, and other undisclosed investors. Ceres is developing improved seed varieties--including. READ MORE>>.
Every year, at the end of the year, we share some reflections on the past year from our readers, entrepreneurs, venture capitalists, sponsors, and others in the local technology community. Many jobs have been created and companies have received funding through our efforts of supporting and bringing value to founders.
The firm, which is headed by Zorik Gordon, was venture backed by VantagePoint Venture Partners, Rho Ventures, Galleon Group, European Founders Fund, and others. The firm sold 4,166,667 shares of stock at $13.00 per share, after pricing below its initial offering range on Wednesday evening, and had traded as high as $15.26 during the day.
ThousandOaks-based wireless networking equipment maker Xirrus has been acquired by Riverbed , to help bolster its SD WAN efforts, the two said on Wednesday. Financial terms of the acquisition were not announced. Riverbed said it will continue to offer up Xirrus as a stand-alone enterprise WLAN solution. READ MORE>>.
ThousandOaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. In addition to Amgen, Adheron has received venture capital from Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, and SROne.
ThousandOaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M As part of the funding, F-Prime's Thomas Beck and Ben Auspitz have joined the company's board. in a Series A investment. The investment came from F-Prime Capital Partners.
in a funding round. I grew up in ThousandOaks, went to USC, and we met each other way back in the 90's. We said, let's create a technology marketplace and platform that creates benefits for those existing lenders, as well as investors. He went into law, then into real estate law, and then into technology.
Home About Us Newsstand locations Special Section Nominations Stock Index Advertising Contact Search Subscribe Weekly Features Week in Review Top 25 Lists Top Stories Local News Opinion Calendar Ongoing Events Monthly Reports Central Coast East Ventura Nonprofits Technology Small Business Women and Co.
ThousandOaks-based Teledyne Technologies said today that it has agreed to acquire FLIR Systems, which develops infrared cameras and similar technology, in a deal worth $8.0 Teledyne said that it is funding the death through a $4.5 According to Teledyne, the cash and stock transaction is split between $28.00
They wanted to do 3-D X-rays, but at the time, there was not technology available to do that. How are you funding this project? This is really also funded because of Mike and my other project, the 101 incubator. Mike Outmesguine: They wanted to do X-rays instead. Instead, we could do that in real time through the cloud.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content